According to FIRS around 384 million people suffer from chronic obstructive pulmonary disease (COPD)

Chronic obstructive pulmonary disease (COPD) and asthma devices are permanent treatment or rescue therapy for respiratory diseases. The COPD and asthma are the respiratory diseases that cause difficulty in breathing and a blockage in the airways of the lungs because of the inflammation, mucus production, and tightening of muscles. The daily exposure to environmental pollution, portability of the drug delivery devices, rising population of active smokers and increasing government initiatives for COPD and Asthma Devices are the few factors responsible for growth.

Request a Sample copy Here @ https://bit.ly/3qUGS8k

For instance: according to the Forum of International Respiratory Societies (FIRS), around 384 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, thus making it the third leading cause of death worldwide. Moreover, increase in prevalence of respiratory diseases such as COPD, asthma, and emphysema, rise in need for rescue medication during sudden asthmatic attack and government initiatives towards the spread of awareness for COPD and asthma symptoms will create a lucrative demand for the Industry.

Key Major Business Manufacturer are: Aerogen, Inc., AstraZeneca PLC, Baxter International Inc., Boehringer Ingelheim International GmbH, 3M COMPANY, GF Health Products, GlaxoSmithKline Plc, Koninklijke Philips N.V., Novartis AG, PARI medical Holding GMBH, Smith’s Group Plc.